Hendra Susanto
The clinician and research community focus on the increasing global prevalence of metabolic syndrome and cancer. Prevention of the high incidence of these two pathological conditions is urgent to suppress the mortality progression in patients. Therefore, exploring potential biomarkers that have a significant correlation to the two events was crucial. Betatrophin, a liver-derived hormone, plays a pivotal role in the pathogenesis of hypertriglyceridemia, metabolic disorders, and cancer development. The in vivo and clinical study was done to characterize betatrophin activity in several diseases. In the last decade, it has been reported that this hormone significantly contributes to metabolic syndrome, obesity, diabetes mellitus, diabetic nephropathy, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and colorectal carcinoma. Furthermore, the animal model and clinical investigation proved that the significant alteration of betatrophin may contribute to those several pathogenic conditions. Betatrophin may induce lipid metabolism disorder and trigger physiological and cellular changes. On the other hand, physical activity intervention with moderate-intensity exercise treatment also decreased the circulating level of betatrophin in subjects with metabolic syndrome symptoms. Hence, the future exploration of this liver potential hormone as a serological biomarker for metabolic syndrome and cancer-linked metabolic disorders could benefit clinical studies. © 2025 American Institute of Physics Inc.. All rights reserved.
Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Negeri Malang, Malang, Indonesia
